The number of adults diagnosed with diabetes has more than quadrupled since 1990 and now stands above 800 million, according to new data released in The Lancet on World Diabetes Day.  The data was part of an analysis conducted by the NCD Risk Factor Collaboration,

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of weekly injections. The results suggest that tirzepatide - the active ingredient in Lilly's diabetes drug Mounjaro and weight-loss treatment Zepbound - could prevent one new case of diabetes for every nine patients treated.

There’s been lots of attention on type 2 diabetes drugs recently, especially since they might also be able to support weight loss. Whether you have type 2 diabetes or obesity, you may have heard about medications like Ozempic® that can help manage blood sugar levels and weight.

Tirzepatide shows promise in reducing weight and preventing diabetes progression in people with obesity and prediabetes, with lasting benefits and manageable side effects.

Nearly 99% of people with prediabetes and obesity or overweight who took weekly tirzepatide injections remained diabetes-free for over three years of using the drug, according to new data from the drugmaker Eli Lilly.

Eli Lilly has reported comprehensive outcomes from the SURMOUNT-1 study of tirzepatide (Zepbound and Mounjaro) for treating pre-diabetic and obese individuals. Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type 2 diabetes (T2D) who were either obese or overweight with complications such as cardiovascular disease,